EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19

Tsuyoshi Jinda, Shinsuke Mizuno iD, Shunsuke Tatami, Masashi Kasai, Tatsuhiko Ishida

Journal of Paediatrics and Child Health · 2024

DOI: 10.1111/jpc.16569 ↗

At a glance

Journal article in Journal of Paediatrics and Child Health, 2024. Written by Tsuyoshi Jinda and 4 co-authors. Institution: Division of Infectious Diseases, Department of Pediatrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan. Major MEDLINE topics: Adenosine Monophosphate, Antiviral Agents, COVID-19 Drug Treatment. Cited 7 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aim

Remdesivir (RDV) causes liver enzyme elevation in adults; however, the frequency of this elevation in children and the associated risk factors are largely unknown. Therefore, we aimed to examine risk factors for liver enzyme elevation in hospitalised paediatric patients who received RDV.

Methods

This was a retrospective case–control study of all patients aged

Subjects

MeSH terms (MEDLINE)

Adenosine MonophosphateAntiviral AgentsCOVID-19 Drug TreatmentHumansRetrospective StudiesMaleFemaleChildRisk FactorsCase-Control StudiesChild, PreschoolAdolescentInfantAlanine TransaminaseAlanineCOVID-19SARS-CoV-2LiverAspartate Aminotransferases

Author keywords

liver enzyme elevationpaediatric COVID‐19remdesivir

Substances

remdesivirAdenosine MonophosphateAntiviral AgentsAlanine TransaminaseAlanineAspartate Aminotransferases

Authors and institutions

  • Division of Infectious Diseases, Department of Pediatrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
  • Department of Pharmacy, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.

ORCID profiles: Shinsuke Mizuno

Cite

APA

Jinda, T., Mizuno, S., Tatami, S., Kasai, M., & Ishida, T. (2024). Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16569

Vancouver

Jinda T, Mizuno S, Tatami S, Kasai M, Ishida T. Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19. Journal of Paediatrics and Child Health. 2024. doi:10.1111/jpc.16569

BibTeX
@article{Jinda2024,
  author = {Jinda, Tsuyoshi and Mizuno, Shinsuke and Tatami, Shunsuke and Kasai, Masashi and Ishida, Tatsuhiko},
  title = {Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19},
  journal = {Journal of Paediatrics and Child Health},
  year = {2024},
  doi = {10.1111/jpc.16569}
}
Start for free →